🔗 Share this article

While the United States undertakes unprecedented changes to its vaccination guidelines, one figure appears unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by casting doubt on coronavirus vaccines during the pandemic and has zeroed in on potential deaths after Covid immunization in her recent tenure at the FDA.

Proposed Overhauls to Childhood Vaccine Schedule

Health officials had intended to reveal radical changes to the pediatric vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, according to reports – a significant shift that would place the US out of alignment with many the international standard with no evidence for improved outcomes. This reveal has been postponed until the new year.

Instead of the top vaccines chief, Dr. Høeg is listed to present at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to run the office this year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has often pushed for ending certain childhood immunization guidelines in the US so as to align more like the Danish model, a nation with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has no obvious experience in drug development, regulation or management, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the necessary background” for leading the CDER, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in managing a major agency. She has no expertise in industry regulation.”

Previous directors of the center would “grasp legal statutes and the underlying principles of medication creation”, noted Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who ran CBER have had.”

CDER has an enormous portfolio at the FDA, the former commissioner pointed out.

“The public just focuses on the new drug program, but the generic drug division clears thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and each of these must be managed,” Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative element to the role, which manages in excess of 5,000 personnel. “It’s a massive management job, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Programs

In response to questions about Høeg’s qualifications and whether this selection indicates more teamwork among FDA leaders on immunizations, a spokesperson stated that the “questions rely on inaccurate assumptions”.

“This background is consistent with the responsibilities of her position,” the official explained, pointing to the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s new fast-track approval initiative, a contentious rapid drug-approval program that reportedly worried her predecessors. “By what process are these drugs being selected for this voucher program? Who is making the decisions?” Howard asked. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards laxer rules of pharmaceuticals, except for vaccines.”

Documented Track Record on Vaccines

Regarding immunizations, Høeg has a more established, if concerning, track record, Howard have noted. She authored a analysis using unverified public submissions to determine the frequency of heart inflammation following COVID-19 immunization. She counseled the Florida top health official Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the incoming federal leadership featured altering regulations for new vaccines and discontinuing “unnecessary” immunizations, she said post-election on a online show. At the FDA, Dr. Høeg has according to sources suggested excluding teenage boys from receiving COVID-19 vaccines.

“She’s an complete ideologue who starts off with her beliefs and tailors the evidence to retrofit the evidence in a very deceptive, dishonest way,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other contrarians, {like|